Status:

COMPLETED

SomaSignal Tests on Medical Management and Change in Risk in Patients With Diabetes

Lead Sponsor:

Emory University

Collaborating Sponsors:

SomaLogic, Inc.

Conditions:

Diabetes Mellitus, Type 2

Eligibility:

All Genders

40+ years

Phase:

NA

Brief Summary

Despite the development of novel treatments, cardiovascular disease (CVD) remains the leading cause of death and disability. It has been observed in clinical practice, that the use of novel glycemia-l...

Detailed Description

This study is being done to evaluate the use of a new test for the management and treatment of patients who are at high risk of heart disease. The test, called a "SomaSignal Test", makes use of person...

Eligibility Criteria

Inclusion

  • Male and female participants 40 years and older
  • Diagnosis of type 2 diabetes (T2D) \[according to American Diabetes Association (ADA) guidelines\]
  • Able to provide consent
  • Eligible for (per drug label/guidelines) at least one of the following drug classes: sodium-glucose cotransporter 2 inhibitors (SGLT2i), proprotein convertase subtilisin/kexin type 9 (PCSK9i), glucagon-like peptide receptor agonists (GLP-1 RA) but not currently prescribed any of these classes of drugs, or only prescribed PCSK9i

Exclusion

  • Systemic Lupus Erythematous (SLE)
  • Pregnancy
  • Intolerance or contraindication for use of GLP-1 RA, SGLT2i, and PCSK9i
  • History of, an active, or untreated malignancy, in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years prior to, or are receiving or planning to receive therapy for cancer, at screening
  • Inability to understand English (currently, SomaSignal testing information, guides, educational materials, and reports are only available in English.)

Key Trial Info

Start Date :

February 3 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 9 2023

Estimated Enrollment :

143 Patients enrolled

Trial Details

Trial ID

NCT05256706

Start Date

February 3 2022

End Date

December 9 2023

Last Update

January 9 2025

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Grady Health System

Atlanta, Georgia, United States, 30303

2

Emory Hospital Midtown

Atlanta, Georgia, United States, 30308

3

Emory Clinic, Emory University Hospital

Atlanta, Georgia, United States, 30322

4

Emory Hospital

Atlanta, Georgia, United States, 30322